Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Asso…
Victoza
Novo Nordisk Re-Initiates Phase 3 Development of Liraglutide (Victoza) for Obesity Treatment
Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the t…
Novo Nordisk to Launch Victoza in Japan
Novo Nordisk announced that it has received approval for the price of Victoza, a once-daily human GLP-1 analogue for the…
Novo Nordisk Anounces Victoza Cardiovascular Outcomes Trial
Novo Nordisk (NVO) announced today details of the company's cardiovascular outcomes trial for Victoza® (liraglutide [rDN…
Superior Efficacy of Victoza Compared to Januvia in the Treatment of Type 2 Diabetes
Novo Nordisk's new diabetes drug Victoza proved more effective than Merck & Co's Januvia in a head-to-head study publish…
Victoza Improves Blood Sugar Control in Patients with Type 2 Diabetes
According to a Novo Nordisk announcement the results from their LEAD™ 6 extension study show that switching to once-dail…
Novo Nordisk receives US approval for Victoza(R) (liraglutide) for treatment of type 2 diabetes
Novo Nordisk announced that it has received US FDA approval for Victoza® (liraglutide) for the treatment of type 2 diabe…
Novo Nordisk Expects FDA Feedback on Liraglutide Within Days
Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding li…
Novo’s Victoza Awaits Final FDA Approval
Novo Nordisk's CEO, Lars Sorensen, told Reuters at the Reuters Health Summit in New York that the new diabetes drug Vict…
